News
-
Anyone wishing to enter the competition for the new DDL Emerging Scientist award should submit their CV and a 1000-word synopsis of their work by June 30, 2017. The winner will present the DDL Emerging… Read more . . .
-
US grocer Albertsons will begin selling Lupin’s InspiraChamber antistatic valved holding chamber exclusively in more than 1,700 pharmacies in 35 US states, Lupin has announced. The InspiraChamber spacer can be used with one of several… Read more . . .
-
MannKind Corporation has announced the appointment of Michael Castagna as Chief Executive Officer, effective May 25, 2017. Castagna takes over the role from Matthew Pfeffer, who succeeded Alfred Mann as CEO in January 2016. Pfeffer… Read more . . .
-
According to Sunovion, the FDA has issued a complete response letter (CRL) for its NDA for SUN-101/eFlow glycopyrrolate inhalation solution for the treatment of COPD. Sunovion submitted the NDA for SUN-101/eFlow in July 2016, and… Read more . . .
-
Elran Haber, CEO of Therapix Biosciences, which is developing intranasal cannabinoid-based drugs, will step down “to pursue other professional opportunities” after the company concludes its search for “a permanent, US based Chief Executive Officer,” the… Read more . . .
-
Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments,… Read more . . .
-
Generic device company Merxin has announced the launch of its MRX003 dry powder inhaler, an off-the-shelf capsule based DPI intended for generic tiotropium 505j submissions. According to an announcement by Merxin’s sister company Aedestra, the… Read more . . .
-
Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .
-
Vectura has announced that it is presenting positive results from a Phase I clinical study of VR942, an inhaled anti-IL-13 monoclonal fragment antibody, at the American Thoracic Society 2017 International Conference. Vectura is partnered with… Read more . . .
-
Chiesi Group has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s MAA for Trimbow beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide MDI. Chiesi has applied to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.